Yasuhiko Izumi

Dr. Yasuhiko Izumi


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
YIYasuhiko Izumi
Yasuhiko Izumi
YKYutaka Koyama
Yutaka Koyama
The NF-E2-related factor 2 (Nrf2)-antioxidant response element (ARE) pathway is a potential therapeutic target for central nervous system diseases. This review emphasizes the role of oxidative stress and neuroinflammation in neurodegenerative diseases, highlighting the therapeutic potential of Nrf2 activators such as dimethyl fumarate (DMF). DMF, initially administered for treating psoriasis, has demonstrated efficacy in multiple sclerosis and is metabolized to monomethyl fumarate, which may exert significant therapeutic effects. DMF activates the Nrf2-ARE pathway, and recent studies have indicated that its anti-inflammatory effects occur through Nrf2-independent mechanisms. Electrophilic Nrf2 activators, such as DMF, covalently bind to cysteine residues in proteins and modulate their function. We discuss the implications of cysteine residue modifications by DMF, which may cause both therapeutic benefits and potential off-target effects. Furthermore, we propose a chemical proteomics-based drug discovery approach to achieve desired therapeutic effects by selectively covalently modifying cysteines in target proteins. These findings advocate for a broader understanding of the Nrf2-independent mechanisms of electrophilic Nrf2 activators, thereby improving drug discovery strategies that target neurodegenerative diseases while minimizing toxicity.

1 September 2020 in Neuroscience Letters
Verified
Journal Article
Closed access
YIYuri Inose
Yuri Inose
YIYasuhiko Izumi
Yasuhiko Izumi
YTYuki Takada-Takatori
Yuki Takada-Takatori
AAAkinori Akaike
Akinori Akaike
YKYutaka Koyama
Yutaka Koyama
TKToshiaki Kume
Toshiaki Kume

4 November 2019 in Scientific Reports
Verified
Journal Article
Open access
KYKenji Yamamoto
Kenji Yamamoto
YIYasuhiko Izumi
Yasuhiko Izumi
MAMonami Arifuku
Monami Arifuku
TKToshiaki Kume
Toshiaki Kume
HSHideyuki Sawada
Hideyuki Sawada
Emerging evidence implicates α-synuclein oligomers as potential culprits in the pathogenesis of Lewy body disease (LBD). Soluble oligomeric α-synuclein accumulation in cytoplasm is believed to modify neuronal activities and intraneural Ca2+ dynamics, which augment the metabolic burden in central neurons vulnerable to LBD, although this hypothesis remains to be fully tested. We evaluated how intracellular α-synuclein oligomers affect the neuronal excitabilities and Ca2+ dynamics of pyramidal neurons in neocortical slices from mice. Intracellular application of α-synuclein containing stable higher-order oligomers (αSNo) significantly reduced spike frequency during current injection, elongated the duration of spike afterhyperpolarization (AHP), and enlarged AHP current charge in comparison with that of α-synuclein without higher-order oligomers. This αSNo-mediated alteration was triggered by spike-induced Ca2+ release from inositol trisphosphate receptors (IP3R) functionally coupled with L-type Ca2+ channels and SK-type K+ channels. Further electrophysiological and immunochemical observations revealed that α-synuclein oligomers greater than 100 kDa were directly associated with calcium-binding protein 1, which is responsible for regulating IP3R gating. They also block Ca2+-dependent inactivation of IP3R, and trigger Ca2+-induced Ca2+ release from IP3R during multiple spikes. This aberrant machinery may result in intraneural Ca2+ dyshomeostasis and may be the molecular basis for the vulnerability of neurons in LBD brains.

20 February 2022 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
YIYasuhiko Izumi
Yasuhiko Izumi
ATAi Tatsumoto
Ai Tatsumoto
NHNaoko Horiuchi
Naoko Horiuchi
MAMonami Arifuku
Monami Arifuku
MUMomoko Uegomori
Momoko Uegomori
YKYutaka Koyama
Yutaka Koyama
Some chemical Nrf2 inducers possess antioxidant and anti-inflammatory properties. TPNA10168, which was identified from a chemical library as a potential activator of the Keap1-Nrf2-ARE pathway, exhibits a neuroprotective effect against oxidative stress-induced injury. However, it has not been investigated as an anti-inflammatory agent. Here we examined the effect of TPNA10168 on interferon-γ-induced proinflammatory gene expression in mouse microglial BV-2 cells. TPNA10168 significantly reduced the transcription of inflammatory genes, including TNF-α, IL-1β, IL-6, and iNOS; however, the inhibition of proinflammatory cytokine gene expression was not attenuated by inhibitors of Nrf2-regulated enzymes. Furthermore, TPNA10168 showed anti-inflammatory effects, even in Nrf2-deficient cells, and inhibited interferon-γ-induced phosphorylation of extracellular-signal-regulated kinase (ERK). Studies with an ERK pathway inhibitor demonstrated a role for ERK in the transcription of inflammatory genes. These results suggest that TPNA10168 attenuates microglial proinflammatory activation independently of Nrf2, at least in part, by suppressing interferon-γ-induced ERK signaling.

3 July 2025 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
YIYasuhiko Izumi
Yasuhiko Izumi
EKEri Koide
Eri Koide
FKFumika Kobayashi
Fumika Kobayashi
SISaori Ikawa
Saori Ikawa
MTMidai Takayama
Midai Takayama
YKYutaka Koyama
Yutaka Koyama
The nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element (ARE) pathway is a major cellular defense mechanism against oxidative stress through the induction of antioxidant proteins. Chemical inducers of Nrf2 often exhibit anti-inflammatory properties. TPNA10168, originally identified as an Nrf2-ARE activator, has previously been shown to attenuate interferon-γ-induced inflammatory responses in BV-2 microglial cells in an Nrf2-independent manner. However, its anti-inflammatory effects on primary microglia remain unclear. In this study, TPNA10168 significantly suppressed the lipopolysaccharide (LPS)-induced expression of inflammatory genes, including tumor necrosis factor-α, interleukin (IL)-1β, and IL-6, in primary microglia. The anti-inflammatory effects of TPNA10168 persisted even after Nrf2 knockdown. Mechanistic analysis revealed that TPNA10168 inhibited LPS-induced phosphorylation of extracellular signal-regulated kinase, p38 mitogen-activated protein kinase, and nuclear factor-κB (NF-κB) p65 without affecting NF-κB nuclear translocation. These findings indicate that TPNA10168 attenuates microglial activation by inhibiting proinflammatory signaling pathways, in part through Nrf2-independent pathways, and is a promising compound for modulating neuroinflammation.

19 October 2025 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
YIYasuhiko Izumi
Yasuhiko Izumi
NTNorihiko Takeda
Norihiko Takeda
SNShuzo Nishimoto
Shuzo Nishimoto
HNHonoka Niimi
Honoka Niimi
SISayuri Ishizu
Sayuri Ishizu
MUMasafumi Ueda
Masafumi Ueda